TARA · Protara Therapeutics, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | $2.95M | — | — | |
| — | — | — | — | — | — | -$34K | — | — | — | — | — | — | — | — | |
| $53.23M | $42.63M | $31.7M | $24.99M | $16.81M | $21.09M | $11.98M | $3.88M | $11.85M | $21.69M | $18.87M | $12.38M | $6.43M | $3.99M | $5.91M | |
| $23.56M | $21.92M | $17.45M | $18.62M | $20.74M | $26.4M | $22.46M | $3.95M | $9.52M | $8.68M | $9.84M | $8.49M | $4.1M | $3.13M | $2.09M | |
| — | — | — | — | — | — | — | — | — | — | $123K | $57K | $30K | $27K | $57K | |
| — | — | — | — | — | — | — | $2.85M | — | — | — | — | — | — | — | |
| $76.79M | $64.55M | $49.15M | $43.61M | $67.06M | $47.49M | $34.44M | $7.83M | $21.37M | $30.36M | $28.71M | $20.87M | $10.53M | $7.12M | $8M | |
| -$76.79M | -$64.55M | -$49.15M | -$43.61M | -$67.06M | -$47.49M | -$34.44M | -$7.83M | -$21.37M | -$30.36M | -$28.71M | -$20.87M | -$7.58M | -$7.12M | -$8M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -257.12% | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$28.58M | -$20.81M | -$7.55M | -$7.1M | -$7.94M | |
| — | — | — | — | — | $0 | $34K | — | — | — | — | — | $857K | $861K | — | |
| $6.53M | $6.38M | $4.17M | $3.19M | $1.11M | $237K | $500K | — | — | — | — | — | — | — | — | |
| $6.78M | $7.11M | $4.56M | $3.19M | $1.11M | $237K | $466K | $262K | $643K | $398K | $179K | -$507K | $4.24M | -$790K | $26K | |
| — | $57.35M | $44.56M | — | — | — | — | -$14.99M | -$20.73M | -$29.96M | -$28.53M | -$21.38M | -$3.34M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$110K | $92K | -$140K | |
| -$69.98M | -$57.44M | -$44.6M | -$40.42M | -$65.95M | -$47.25M | -$33.98M | -$7.83M | -$20.73M | -$29.96M | -$28.53M | -$21.38M | -$3.34M | -$7.91M | -$7.97M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -113.36% | — | — | |
| — | — | — | -$40.42M | -$65.95M | $47.25M | $33.98M | — | -$20.73M | -$36.71M | -$28.53M | -$21.38M | -$9.7M | -$14.03M | -$14.1M | |
| -$70.46M | -$57.35M | -$44.56M | -$39.76M | -$66.43M | -$47.46M | -$33.98M | -$14.99M | -$20.71M | -$29.98M | -$28.52M | -$21.38M | -$3.35M | -$7.91M | — | |
| USD/shares | — | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | — | — | — | — | — | — | — | — | — |
| shares | — | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 2.58M | 452.56K | 431.86K | 414.04K | 411.6K | 76.61K | 5879.6 | 5765.175 |
| shares | — | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 2.58M | 452.56K | 431.86K | 414.04K | 411.6K | 76.61K | 5879.6 | 5765.175 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $409K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 315 similar-size Biotechnology companies (of 534 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | -$64,549,000 | -$49,154,000 |